Stryker stock rises 11.4% weekly despite lower 2026 outlook
Published on 11/07/2026 at 11:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOutlook Cut Meets Weekly Stock Gain
- Stryker lowered its 2026 organic sales-growth forecast after third-quarter results showed slower hip and knee procedures.
- Management cited broader economic pressure, higher insurance costs and delayed patient decisions as factors affecting joint-replacement demand.
- The company is also preparing a leadership transition, with Spencer Stiles set to succeed Kevin Lobo as chief executive in January.
Stryker stock traded at 292.45 euros on Lang & Schwarz at 11:08 CET on Saturday, November 7, 2026, 0.22 percent above the Xetra close of Friday, November 6. The share was 11.37 percent higher than the Xetra close of Friday, October 30, giving the week a positive market profile despite a lower full-year outlook.
The medical-device maker lowered its 2026 organic sales-growth guidance to 6.5 to 7.0 percent from 8.3 to 9.3 percent after third-quarter performance fell short of expectations. MedTech Dive reported on October 30 that Stryker saw fewer hip and knee procedures than expected, with knee sales up 1.1 percent year over year and hip sales down 1 percent.
Joint Replacement Demand Slows
Chief Executive Kevin Lobo attributed the slowdown to broader economic concerns. The report said higher insurance premiums and deductibles, as well as pre-authorization denials, were delaying procedures for some patients. The company also faced a cyberattack and a software implementation in its orthopedics business during the year.
Third-quarter revenue reached 6.5 billion US dollars, up 7.7 percent year over year, while net earnings fell 12.3 percent to 753 million US dollars, according to MedTech Dive. Management also reduced its adjusted 2026 earnings-per-share outlook to 14.80 to 14.90 US dollars.
Margin expansion and expense discipline provide support for profitability, but the revised guidance leaves investors focused on procedure volumes and execution in orthopedics. Stryker has not issued formal 2027 guidance in the reviewed coverage.
Stryker Corporation at a Glance
- Company: Stryker Corporation
- ISIN: US8636671013
- Home ticker: SYK
- Home exchange: New York Stock Exchange
- Lang & Schwarz quote: 292.45 euros, November 7, 2026, 11:08 CET
- Weekly change: 11.37 percent versus the Xetra close of October 30, 2026
- Xetra close: 291.80 euros on November 6, 2026
- Sector: Medical devices
View the real-time quote of Stryker stock for the latest trading indication.
Broader sentiment for US equities can be followed through current S&P 500 market developments.
More news and analyses are available on Stryker stock.
